Compare Duolingo Inc (DUOL) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Duolingo Inc vs BIO-TECHNE Corp — how do they compare? Duolingo Inc trades at $134.83 (market cap $6.42B), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: BIO-TECHNE Corp is the larger of the two by market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Duolingo Inc pays none. Which is the better fit depends on your goals.
| DUOL | TECH | |
|---|---|---|
Market Cap | $6.42B | $11.24B |
Sector | Technology | Health |
52-Week High | $369.19 | $72.29 |
52-Week Low | $90.03 | $43.31 |
Enterprise Value | $5.19B | $11.32B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DUOL trades at $130.9, up 6.79% in 24 hours, with a neutral technical signal. The company reported strong Q2 2026 earnings, beating EPS estimates at $0.66 versus $0.604 expected, driven by 23% daily active user growth. However, a lower Q3 revenue forecast has tempered optimism. Fundamentals show robust revenue growth to $1.04B in 2025 and a net income margin of 35.87%, though valuation multiples like P/E of 15.47 and P/S of 5.6 suggest premium pricing.
Outlook is mixed: strong user engagement and profitability support upside, but monetization concerns and competitive pressures pose risks. Analysts are cautious with a $121 consensus price target below current levels, highlighting execution challenges in converting growth to sustained revenue.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Duolingo Inc
Duolingo Inc is a mobile learning platform to learn languages and the top-grossing app in the Education category on both Google Play and the Apple App Store. It has three predominant sources of revenue
Read more on DUOL →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
